0000000000208690

AUTHOR

Peter Verhamme

0000-0001-8698-2858

showing 8 related works from this author

Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis.

2018

Lemierre syndrome usually affects otherwise healthy adolescents or young adults and occurs at an overall rate of 1 to 10 cases per million person-years with an estimated fatality rate of 4 to 9%. Diagnostic criteria remain debated and include acute neck/head bacterial infection (often tonsillitis caused by anaerobes at high potential for sepsis and vascular invasion, notably Fusobacterium necrophorum) complicated by local vein thrombosis, usually involving the internal jugular vein, and systemic septic embolism. Medical treatment is based on antibiotic therapy with anaerobic coverage, anticoagulant drugs and supportive care in case of sepsis. Surgical procedures can be required, including d…

AdultMalemedicine.medical_specialtyTonsillitisved/biology.organism_classification_rank.species030204 cardiovascular system & hematologySepsis03 medical and health sciencesYoung Adult0302 clinical medicineFusobacterium necrophorumJugular veinCase fatality ratemedicineHumansIntensive care medicine610 Medicine & healthInternal jugular veinSeptic embolismVenous Thrombosisbusiness.industryved/biologyAnticoagulantsHematologyLemierre Syndromemedicine.diseaseLemierre Study GroupPrognosisAnti-Bacterial AgentsVenous thrombosisFusobacterium necrophorumbusiness030215 immunologyHamostaseologie
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

C0307 Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineBaseline characteristicsmedicineCardiologyHematologybusinessSurgeryThrombosis Research
researchProduct

C0322 Factors associated with therapeutic strategies in patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineCardiologymedicineIn patientHematologybusinessThrombosis Research
researchProduct

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy

2019

AbstractThe most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60%…

Carotid Artery DiseasesMaleRisk0301 basic medicinemedicine.medical_specialtyCardiologyHemorrhageThromboembolic stroke030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineRivaroxabanCarotid artery diseaseInternal medicineIschaemic strokeMyocardial RevascularizationmedicineHumansAgedAspirinbusiness.industryIncidence (epidemiology)Atherosclerotic diseaseAnticoagulantsAtrial fibrillationHematologyMiddle AgedAtherosclerosismedicine.diseaseClopidogrelReview articleCarotid Arteries030104 developmental biology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCardiovascular Diseasesanti-platelet; anti-thrombotic therapy; anticoagulant; aspirin; carotid artery disease; rivaroxabanCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessPlatelet Aggregation InhibitorsThrombosis and Haemostasis
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study

2019

AimsWe studied the association of circulating metabolic biomarkers with asymptomatic left ventricular diastolic dysfunction, a risk-carrying condition that affects 25% of the population.Methods and resultsIn 570 randomly recruited people, we assessed in 2005–2010 and in 2009–2013 the multivariable-adjusted correlations of e’ (early left ventricular relaxation) and E/e’ (left ventricular filling pressure) measured by Doppler echocardiography with 43 serum metabolites, quantified by magnetic resonance spectroscopy. In 2009–2013, e’ cross-sectionally increased (Bonferroni corrected p ≤ 0.016) with the branched-chain amino acid valine (per one standard deviation increment, +0.274 cm/s (95% conf…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance SpectroscopyTime FactorsEpidemiology030204 cardiovascular system & hematologyVentricular Function LeftVentricular Dysfunction Left0302 clinical medicineBelgiumpopulation scienceDiastole030212 general & internal medicinebranched-chain amino acidsMetabolic biomarkersVentricular functionIncidenceMiddle AgedRNA Transfer Amino Acid-SpecificPrognosismetabolomicsEchocardiography DopplerGLUTAMINECardiologyPopulation studyHEART-FAILUREFemalemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyDiastoleAsymptomatic03 medical and health sciencesPredictive Value of TestsInternal medicineATRIALmedicineHumansAgedScience & Technologybusiness.industryBiomarkerDYSFUNCTIONBiomarker (cell)diastolic left ventricular dysfunctionAsymptomatic DiseasesCardiovascular System & CardiologyLeft ventricular diastolic dysfunctionTransfer RNA AminoacylationbusinessAmino Acids Branched-ChainBiomarkers
researchProduct